Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19

Reuters2021-07-06

July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
30